益盛药业(002566) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 200,387,679.60, a decrease of 20.16% compared to CNY 250,973,766.69 in the same period last year[3] - Net profit attributable to shareholders was CNY 21,016,379.98, down 26.78% from CNY 28,702,562.15 year-on-year[3] - Basic earnings per share were CNY 0.0635, reflecting a decline of 26.76% from CNY 0.0867 in the same period last year[3] - Net profit for Q1 2024 was CNY 21,416,406.19, down 31.7% from CNY 31,391,147.16 in Q1 2023[19] - Earnings per share (EPS) decreased to CNY 0.0635 from CNY 0.0867, representing a decline of 26.5%[20] - Total operating costs decreased to CNY 178,722,040.00 from CNY 221,979,729.88, reflecting a reduction of approximately 19.5%[17] Cash Flow - The net cash flow from operating activities decreased by 46.75%, amounting to CNY 42,774,958.89 compared to CNY 80,326,480.85 in the previous year[3] - Cash flow from operating activities generated CNY 42,774,958.89, down 46.8% from CNY 80,326,480.85 in the previous year[20] - The net cash flow from investment activities was 39,505,505.47, compared to a cash outflow of 22,558,579.13 in the previous period, indicating a significant improvement[21] - The total cash inflow from financing activities was 140,000,000.00, down from 190,000,000.00 in the previous period, reflecting a decrease of approximately 26.3%[21] - The net cash flow from financing activities was -4,362,461.17, a decline from a positive cash flow of 34,120,789.55 in the previous period, showing a substantial decrease[21] - The net increase in cash and cash equivalents for the period was 77,918,003.19, compared to 91,888,691.27 in the previous period, representing a decrease of about 15.2%[21] - The ending balance of cash and cash equivalents was 565,651,644.14, up from 435,152,569.03 in the previous period, indicating an increase of approximately 30%[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,055,167,016.64, a slight increase of 0.28% from CNY 3,046,722,440.31 at the end of the previous year[3] - Total assets reached RMB 3,055,167,016.64, up from RMB 3,046,722,440.31, reflecting a total asset growth of approximately 0.3%[15] - Total liabilities decreased to RMB 701,329,868.67 from RMB 714,301,698.53, marking a reduction of about 1.8%[15] - The company reported a total current assets of RMB 2,450,747,115.54, slightly up from RMB 2,431,067,051.02, indicating a growth of about 0.8%[14] - The company’s non-current assets totaled RMB 604,419,901.10, down from RMB 615,655,389.29, reflecting a decrease of approximately 1.9%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,052, with the largest shareholder holding 39.08% of the shares[9] - The company is addressing issues related to shareholding transparency by reducing the number of shares held in trust by certain shareholders[11] - The company plans to ensure accurate information disclosure during the reduction of shares held by shareholder Liu Jianming[11] Other Information - The company reported a total of CNY 2,921,548.25 in non-recurring gains and losses for the period, primarily from government subsidies and asset disposals[4] - The company established a wholly-owned subsidiary, Yisheng Ginseng (Hangzhou) Health Technology Co., Ltd., with a registered capital of RMB 3 million[13] - The company has not reported any new product developments or market expansion strategies in this quarter[1] - Research and development expenses were CNY 5,008,860.86, slightly down from CNY 5,323,126.61, indicating a focus on cost management[17] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[22]